🇺🇸 Remifentanyl in United States

35 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Anaphylactic Shock — 8 reports (22.86%)
  2. Cardiac Arrest — 4 reports (11.43%)
  3. Anaphylactic Reaction — 3 reports (8.57%)
  4. Atrioventricular Block Second Degree — 3 reports (8.57%)
  5. Bradycardia — 3 reports (8.57%)
  6. Dystonia — 3 reports (8.57%)
  7. Myalgia — 3 reports (8.57%)
  8. Pancreatitis Necrotising — 3 reports (8.57%)
  9. Syncope — 3 reports (8.57%)
  10. Anaphylactoid Reaction — 2 reports (5.71%)

Source database →

Remifentanyl in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Pain approved in United States

Frequently asked questions

Is Remifentanyl approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for Remifentanyl in United States?

Kocaeli University is the originator. The local marketing authorisation holder may differ — check the official source linked above.